GREENWICH LIFESCIENCES INC

Greenwich LifeSciences is a clinical-stage biopharmaceutical company whose core business model involves animal testing. The company’s lead product candidate, GP2, is an immunotherapy for breast cancer currently in clinical trials. Preclinical development of such biologics, including toxicology studies and efficacy testing, is conducted in animal models as a standard regulatory requirement. This constitutes commercial exploitation of animals for product development.

An audit of U.S. laboratories published in November 2025 documented hundreds of animal welfare violations, providing evidence of widespread suffering and systemic compliance failures in the industry. While the report did not name Greenwich LifeSciences specifically, the company operates within this same regulatory and research ecosystem where such violations are prevalent. The company’s own SEC filings acknowledge operational risks, including “intentional failures to comply with FDA regulations,” which encompass the Animal Welfare Act and guidelines for humane animal research.

The company has not published an animal welfare policy or committed to adopting non-animal testing methodologies where scientifically valid alternatives exist. Its business remains dependent on animal testing to advance its clinical pipeline.